Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Accéder directement au contenu
Article Dans Une Revue JACC : Basic to Translational Science Année : 2020

Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab

Résumé

Lipoprotein(a) (Lp[a]) is the most common genetically inherited risk factor for cardiovascular disease. Many aspects of Lp(a) metabolism remain unknown. We assessed the uptake of fluorescent Lp(a) in primary human lymphocytes as well as Lp(a) hepatic capture in a mouse model in which endogenous hepatocytes have been ablated and replaced with human ones. Modulation of LDLR expression with the PCSK9 inhibitor alirocumab did not alter the cellular or the hepatic uptake of Lp(a), demonstrating that the LDL receptor is not a major route for Lp(a) plasma clearance. These results have clinical implications because they underpin why statins are not efficient at reducing Lp(a). (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
Fichier principal
Vignette du fichier
1-s2.0-S2452302X20301248-main.pdf (773.95 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03211827 , version 1 (29-04-2021)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Kévin Chemello, Sandra Beeské, Thi Thu Trang Tran, Valentin Blanchard, Elise Villard, et al.. Lipoprotein(a) Cellular Uptake Ex Vivo and Hepatic Capture In Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab. JACC : Basic to Translational Science, 2020, 5 (6), pp.549-557. ⟨10.1016/j.jacbts.2020.03.008⟩. ⟨hal-03211827⟩
53 Consultations
73 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More